The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective ...

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...

Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and ...

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while ...

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...